As scientists, we are challenged to discover treatments for cancer patients. Yet, the lack of available models relevant to tumor type, disease progression, and population diversity impedes our progress towards rapid advancements in translational medicine.
We are committed to providing authenticated cancer models that lead to breakthroughs in translational research. To this end, ATCC produces the materials and standards for drug screening, tumor mechanisms, cancer immunology, and cancer diagnostics that scientists need to accomplish innovative research. New models such as organoids, conditionally reprogrammed cells, luciferase expressing reporter cell lines, isogenic CRISPR/Cas9 genome-edited cell lines, and epithelial-mesenchymal transition reporter cell lines are essential for your cutting-edge cancer research.
In the fight against cancer, we can provide you with access to a wide variety of model systems to elucidate the mechanisms behind the growth and metastasis of each cancer tumor type. ATCC offers a wide variety of cancer cell lines related to cancer genetics, early detection methods, and effective treatments of disease.
See our products for oncology drug development
Cancer immunology research tools
Boost your cancer immunology research with well authenticated and characterized cell models focused on advancing areas such as cancer cell-directed therapies.
The immune system is central to many forms of cancer, being critical in both its development and its treatment, including immune cell-directed therapies.
Boost your cancer immunology research with well authenticated and characterized cell models focused on advancing areas such as cancer cell-directed therapies.
Primary Human Immune Cells
ATCC primary immune cells support complex, physiologically relevant research projects, including toxicity screening, transplantation and graft rejection, inflammation and allergy, vaccine, drug development, and cancer immunology studies.
Progenitor Cells
Hematopoietic progenitor cells are capable of differentiating into all blood cell types. Understanding progenitor cells and the cells that derive from them is critical to many fields, including hematology, immunology, and oncology.
The immune system is central to many forms of cancer, being critical in both its development and its treatment, including immune cell-directed therapies.
Lymphoid Cells
Lymphoid cells provide long-lasting immunity against microbes and pathogens and are essential in fields such as autoimmunity and cancer immunotherapies. Human primary lymphoid cells provide physiological relevance to your research.
Natural Killer Cells
Natural killer (NK) cells were first identified for their ability to kill tumor cells without activation. NK cells are a focus of many cancer immunotherapies, as they display rapid and potent immunity to metastasis or hematological cancers.
Drug screening tools
As part of our pledge to elevate biological models, ATCC offers well-characterized cell lines, organoids, primary and hTERT immortalized cells, iPSCs and CRISPR/Cas9 genome-edited cells.
ATCC models support the development and evaluation of high-throughput screening assays for the rapid assessment of pharmaceutical efficacy and compound toxicity.
As part of our pledge to elevate biological models, ATCC offers well-characterized cell lines, organoids, primary and hTERT immortalized cells, iPSCs and CRISPR/Cas9 genome-edited cells.
Isogenic Cell Lines
With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes--ideal for identifying novel, treatment regimens.
Chordoma Cells
ATCC, in partnership with the Chordoma Foundation, offers authenticated chordoma cell lines for the development of treatments and therapeutic targets for chordoma, a rare, slow-growing spinal cancer.
ATCC models support the development and evaluation of high-throughput screening assays for the rapid assessment of pharmaceutical efficacy and compound toxicity.
Next-generation Cancer Models
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids and conditionally reprogrammed cells (CRCs).
hTERT immortalized Primary Cells
ATCC human telomerase reverse transcriptase (hTERT) immortalized primary cell lines represent a breakthrough in cell biology research that combines the in vivo nature of primary cells with the traditional cell line's ability to survive continuously in vitro.
Tumor mechanisms
Cancer researchers need a wide variety of model systems to isolate the mechanisms behind the growth and metastasis of each tumor type.
ATCC can provide the tools you need for your cancer research.
Cancer researchers need a wide variety of model systems to isolate the mechanisms behind the growth and metastasis of each tumor type.
EMT/MET Reporter Cell Lines
ATCC scientists used CRISPR/Cas9 technology to create gene-edited EMT and MET reporter cell lines that enable real-time monitoring of the transition of cells from epithelial to mesenchymal state (or the reverse) via the expression of red fluorescent protein (RFP)–tagged vimentin or green fluorescent protein (GFP)–tagged E-cadherin.
Luciferase-labeled Cell Lines
These advanced models provide a relatively simple, robust, and highly sensitive means to measure biological processes and to assess drug efficacy in live animal models through bioluminescence imaging.
ATCC can provide the tools you need for your cancer research.
Epithelial cells
Primary epithelial cells are valuable tools for modeling the barriers between the inside and outside of the body and used in a variety of applications from cancer research to toxicology.
CRISPR Cas9 engineered Cancer Models
This white paper discusses research targeting the specific molecular pathways driving tumor proliferation rather than killing all rapidly dividing cells as in traditional chemotherapy. Targeted therapies could turn a dire prognosis into a manageable condition.
Cancer diagnostics
Scientists are continually designing laboratory and genetic assays to detect the tumor biomarkers that are constantly discovered.
ATCC has the tools you need to test your clinical laboratory assays, imaging techniques, and genomic analyses.
Scientists are continually designing laboratory and genetic assays to detect the tumor biomarkers that are constantly discovered.
Matched Normal and Tumor Cell Lines
ATCC offers Tumor/Normal matched cell line pairs derived from the same donor, allowing researchers to compare the experimental results from tumor cell lines to that of their normal counterparts.
Cancer Panels
ATCC offers a wide variety of cancer cell lines for use in research related to cancer genetics, early detection methods, and effective treatment of disease.
ATCC has the tools you need to test your clinical laboratory assays, imaging techniques, and genomic analyses.
Quantitative Cell Line DNA
ATCC qDNA are extracted cell lines that contain biomarkers that have been quantified by validated methods for each product lot. Gene mutation allelic frequency as well as relative and absolute gene copy number are available for each qDNA.
Exosomes
ATCC offers exosomes derived from well-authenticated cell lines and hTERT-immortalized mesenchymal stem cells. These extracellular vesicles can be used as standards for creating diagnostic tests and studying exosome composition, epigenetic reprogramming of cells, and disease markers.
Cancer research tools
Primary Immune Cells
ATCC has the primary immune cells, including peripheral blood mononuclear cells (PBMCs), you need to design and test cell-based assays and treatments as part of your research and development. A typical vial of PBMCs includes progenitor populations such as CD14+ monocytes and lymphocytes such as cluster of differentiation (CD) 19+ B cells, CD4+ helper T cells, CD8+ cytotoxic T cells, and CD56+ natural killer (NK) cells.
Learn More
Media and Reagents
ATCC high-performance media, sera, and reagents are uniquely formulated according to the cell growth conditions.
Get the Tools
